ROIV
Roivant Sciences Ltd.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.62
P/S
1523.35
EV/EBITDA
-18.72
DCF Value
$3.21
FCF Yield
-3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.2%
Operating Margin
-9130.5%
Net Margin
-6079.9%
ROE
-18.3%
ROA
-15.5%
ROIC
-23.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.0M | $-265.9M | $-0.38 |
| Q2 2025 | $1.6M | $-113.5M | $-0.17 |
| Q1 2025 | $2.2M | $-223.4M | $-0.33 |
| Q4 2024 | $7.6M | $-206.5M | $-0.29 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
GB
Exchange
NASDAQ
Beta
1.21
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.